← Eichor
Condition: Stage Iii Lung Non Small Cell Cancer Ajcc V7 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Stage Iii Lung Non Small Cell Cancer Ajcc V7

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tumor Treating Fields for Locally Advanced NSCLC
Phase 1 · 1 location(s) · University of Utah · NCT06124118Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03872661Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stag
Phase 2 · 25 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06656598Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT06634056A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT05940532The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment
Phase 2 · 1 location(s) · The Third Xiangya Hospital of Central South University · NCT07138755The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
NA · 27 location(s) · Radboud University Medical Center · NCT06082492Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04892953A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lu
Phase 2 · 43 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT06667908Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT03694236PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Phase 2 · 11 location(s) · TheraOp · NCT06102057Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Phase N/A · 6 location(s) · University Medical Center Groningen · NCT06111807Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06563999Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung C
Phase 2 · 1 location(s) · Fondazione Ricerca Traslazionale · NCT05568212Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Local
Phase 1/Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07632365Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 1 location(s) · Fondazione Ricerca Traslazionale · NCT07264647A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06623487A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresec
Phase 3 · 256 location(s) · Bristol-Myers Squibb · NCT07361497IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2/Phase 3 · 11 location(s) · Swiss Cancer Institute · NCT07149649Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapse
Phase 2 · 9 location(s) · Mario Negri Institute for Pharmacological Research · NCT06680050Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Phase 4 · 1 location(s) · Idris Bahce · NCT06908070Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
NA · 1 location(s) · Ruijin Hospital · NCT05557552Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in S
Phase 3 · 1 location(s) · Maximilian Diehn · NCT04585490Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
NA · 1 location(s) · Danish Lung Cancer Group · NCT03742687Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Phase 2 · 1 location(s) · Wake Forest University Health Sciences · NCT05696782Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT04728724
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.